# Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)

> **NCT01181115** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 60 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Avonex

## Key facts

- **NCT ID:** NCT01181115
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01181115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01181115, "Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01181115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*